Publications
& Policy

Why we need to mobilize private growth capital and how we can do it.

In this response, we express serious concerns about the introduction of the proposed guidelines on funds’ names, which we believe amounts to rulemaking which is not within the powers of ESMA. Should ESMA nonetheless introduce guidelines, we urge ESMA inter alia to include more elaborate grandfathering and transitional relief and to delete the suggested minimum safeguards.

Get fully up-to-date on the new European Long-Term Investment Fund (ELTIF) framework by listening to this webinar.

An outlook on the different climate innovations European firms are currently using, their motivations and challenges, and their views on current regulatory frameworks.

The index, launched in 2006, tracks the valuations of eurozone private, mid-market companies in which a majority stake has been acquired during the last six months.

The importance of venture capital in the EU’s life science industry.

Invest Europe replied to the BEFIT public consultation. In this document Invest Europe supports the main objectives of BEFIT as set out in the Call for Evidence, but in addition recognises the need for further clarifications due to the high-level description of the BEFIT rules.

Altogether 33 Finnish general partners of venture capital and private equity funds responded to the questionnaire. This represents some 90% of the players, almost the entire market.

Exploring Europe's deep tech credentials, hurdles and opportunities.

In this response, we share our views on the possible features and risks of greenwashing in the financial services sector. Among others, we note that the complexity, lack of clarity around key concepts and moving goalposts with each iteration of guidance/Q&As under the current SFDR regime are a major source of greenwashing risk.

In this response Invest Europe comments on the inadequacy of the concept of a "single undertaking" which does not sufficiently take into consideration the nature of private equity investments, at the risk of making it harder for private equity-backed businesses to receive financial support from the state.

Ecares: The entry of private equity investors into the healthcare sector may lead to negative impacts on coverage, pricing, and quality, due to the margin for cream-skimming allowed to these firms to ease their entry in the sector.

Institutional Investor: It is hard to value private assets such as private equity, venture capital, and real estate investments.